Camlosart 5/20mg 10pcs

Indications

Two medications, both of which help to control high blood pressure, are present in Camlosart 5/20. Your likelihood of experiencing a heart attack or stroke in the future is decreased by lowering blood pressure. You can take Camlosart on 5/20 with food or on an empty stomach. It is best to take it regularly, as directed by your doctor, at a set time each day.

Pharmacology

Amlodipine is a dihydropyridine calcium channel blocker that prevents calcium ions from passing through the membrane into the myocardium and vascular smooth muscle. Amlodipine has a greater impact on vascular smooth muscle cells than it does on cardiomyocytes. Amlodipine reduces peripheral vascular resistance and blood pressure by directly acting on vascular smooth muscle, which is how it works as a peripheral arterial vasodilator.

The angiotensin-converting enzyme catalyzes the reaction that results in the formation of angiotensin II from angiotensin I. (ACE). It is the primary vasoactive hormone of the renin-angiotensin system and a potent vasoconstrictor. It has high blood pressure as well. a crucial aspect of pathophysiology. Additionally, it induces aldosterone secretion from the adrenal cortex.

Olmesartan medoxomil selectively prevents angiotensin II from binding to AT1 receptors found in numerous tissues, preventing angiotensin II from constricting blood vessels and secreting aldosterone (such as vascular smooth muscle, and adrenal glands). Olmesartan Medoxomil is a competitive and reversible AT1 receptor inhibitor, according to in vitro binding studies. Olmesartan medoxomil doesn't stop ACE from working (kinase II, an enzyme that converts angiotensin I into angiotensin II and breaks down bradykinin).

Dosage & Administration

Initial Treatment One tablet (5/20 mg) taken once daily is the typical starting dose for CamlosartTM. After one to two weeks of therapy, the dosage can be increased to a maximum of 10/40 mg once daily as needed to control blood pressure. You can take CamlosartTM with or without food. It is possible to combine CamlosartTM with other antihypertensive medications. Patients older than 75 or with hepatic impairment should not begin treatment with this combination product. Treatment Replacement

To replace each of its individually titrated components, use CamlosartTM. If blood pressure control has not been successful when using individual components, the dose of one or both of the components may need to be increased. Extension Therapy

For patients whose blood pressure cannot be sufficiently controlled by Amlodipine (or another dihydropyridine calcium channel blocker) alone or by Olmesartan Medoxomil (or another angiotensin II receptor blocker) alone, CamlosartTM may be used.

Interaction

The pharmacokinetics of Amlodipine and Olmesartan Medoxomil is not altered when the drugs are co-administered. No drug interaction studies have been conducted with Amlodipine and Olmesartan combination tablets and other drugs, although studies have been conducted with the individual Amlodipine and Olmesartan Medoxomil components and no significant drug interactions have been observed.

Contraindications

Hypersensitivity to any of the components of this combination product.

Side Effects

• Sleepiness
• Taste change
• Ankle swelling
• Headache
• Flushing (sense of warmth in the face, ears, neck, and trunk)
• Dizziness
• Tiredness
• Palpitations
• Upset stomach
• Increased potassium level in the blood

Pregnancy & Lactation

Pregnancy: When pregnancy is detected, discontinue this combination product as soon as possible. When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus.

Nursing Mothers: Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, considering the importance of the drug to the mother.

Children: The safety and effectiveness of pediatric patients have not been established. 

Precautions & Warnings

Fetal/Neonatal Morbidity and Mortality: This combination medications should be stopped as soon as pregnancy is discovered. Patients who are volume- or salt-depleted may experience symptomatic hypotension after treatment begins. Vasodilation: Use caution when giving this combination to patients, especially those who have severe aortic stenosis. When starting calcium channel blocker therapy or when the dosage is increased, patients with severe occlusive coronary artery disease may experience an increase in the frequency, duration, or severity of angina or an acute MI. Calcium channel blockers should only be used with extreme caution in patients with congestive heart failure. Use with caution in patients with impaired renal function or hepatic impairment.

Storage Conditions

Store in a cool and dry place, protect from light and moisture. Store at 250 C. Keep out of the reach of children